DanielMichaelGeynismanMD

PubMed

• Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.
  Pedro Barata, Shuchi Gulati, Andrew Elliott, Hans J Hammers, Earle F Burgess, Benjamin A Gartrell, Sourat Darabi, Mehmet A Bilen, Arnab Basu, Daniel M Geynisman, Nancy...> ;The Journal of Clinical Investigation. 2024 Apr 23
• Contemporary role of avelumab first-line maintenance in advanced urothelial carcinoma with consideration of the JAVELIN Bladder 100 comprehensive clinical subgroup ana...
  Kevin K Zarrabi, Benjamin Miron, Daniel M Geynisman> ;Translational Andrology and Urology. 2024 Mar 31
• 1 citations
  Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas.
  Wei, S., Krause, H., Geynisman, D., Elliott, A., Kutikov, A., Uzzo, R., Pei, J., Barata, P., Carneiro, B., Heath, E., Ryan, C., Farrell, A., Nabhan, C., Ali-Fehmi, R.,...> ;Modern Pathology. 2024 Feb 1
• "Cancer's a demon": a qualitative study of fear and multilevel factors contributing to cancer treatment delays.
  Frosch, Z., Jacobs, L., O'Brien, C., Brecher, A., McKeown, C., Lynch, S., Geynisman, D., Hall, M., Edelman, M., Bleicher, R., Fang, C.> ;Supportive Care in Cancer. 2023 Dec 7
• Cost-Effectiveness Analysis for Therapy Sequence in Advanced Cancer: A Microsimulation Approach with Application to Metastatic Prostate Cancer.
  Elizabeth A Handorf, J Robert Beck, Andres Correa, Chethan Ramamurthy, Daniel M Geynisman> ;Medical Decision Making. 2023 Oct 9
• 3 citations
  Development of a Multilevel Model to Identify Patients at Risk for Delay in Starting Cancer Treatment.
  Zachary A K Frosch, Jill Hasler, Elizabeth Handorf, Tesla DuBois, Richard J Bleicher, Martin J Edelman, Daniel M Geynisman, Michael J Hall, Carolyn Y Fang, Shannon M L...> ;JAMA Network Open. 2023 Aug 1
• 2 citations
  A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.
  Matthew Zibelman, Alexander W MacFarlane 4th, Kimberly Costello, Thomas McGowan, John O'Neill, Rutika Kokate, Hossein Borghaei, Crystal S Denlinger, Efrat Dotan, Danie...> ;Nature Communications. 2023 Jul 27
• 17 citations
  Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
  Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, Christopher J Hoimes, Thomas W Flaig, Nataliya Mar, Helen H Moon, Terence W Friedlander, Rana R McKay, Mehmet...> ;Journal of Clinical Oncology. 2023 Sep 1
• A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.
  David Pook, Daniel M Geynisman, Joan Carles, Filippo de Braud, Anthony M Joshua, José Luis Pérez-Gracia, Casilda Llácer Pérez, Sang Joon Shin, Bruno Fang, Minal Barve,...> ;Clinical Cancer Research. 2023 Sep 1
• 1 citations
  Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
  Ravi A Madan, Marijo Bilusic, Mark N Stein, Renee N Donahue, Philip M Arlen, Fatima Karzai, Elizabeth Plimack, Yu-Ning Wong, Daniel M Geynisman, Matthew Zibelman, Tina...> ;The Oncologist. 2023 Jul 5
• Between the Hammer and Anvil: Resolution of unresectable muscle invasive bladder cancer in a renal transplant patient after cessation of immunosuppressive therapy.
  David Strauss, Briana Kaplunov, Alexander Kutikov, Daniel M Geynisman, Kwan Lau, Marc Smaldone> ;Urology Case Reports. 2023 May 1
• Corrigendum to real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States [Urologic oncology: Seminars ...
  Daniel M Geynisman, Edward Broughton, Yi Hao, Ying Zhang, Trong Le, Stephen Huo> ;Urologic Oncology. 2023 May 1
• 1 citations
  Current Status and Future Direction to Address Disparities in Diversity, Equity, and Inclusion in Prostate Cancer Care.
  Jerry Fu, Chen Fu, Robert S Wang, Daniel M Geynisman, Pooja Ghatalia, Shannon M Lynch, Sharon R Harrison, Erin K Tagai, Camille Ragin> ;Current Oncology Reports. 2023 Jul 1
• 6 citations
  A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
  H Josh Jang, Galen Hostetter, Alexander W Macfarlane, Zachary Madaj, Eric A Ross, Toshinori Hinoue, Justin R Kulchycki, Ryan S Burgos, Mahvish Tafseer, R Katherine Alp...> ;Clinical Cancer Research. 2023 Jun 1
• 3 citations
  A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
  Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, Cristina Suárez, Maria T Bourlon, Pedro C Barata, Shuchi Gulati, Stephen Huo, Flavia Ejzykowicz, Steven I Blum,...> ;European Urology Oncology. 2023 Jun 1
• 11 citations
  A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasi...
  Noah M Hahn, Michael A O'Donnell, Jason A Efstathiou, Marianna Zahurak, Gary L Rosner, Jeff Smith, Max R Kates, Trinity J Bivalacqua, Phuoc T Tran, Daniel Y Song, Alex...> ;European Urology. 2023 Jun 1
• 2 citations
  Role of perioperative immunotherapy in localized renal cell carcinoma.
  Jasmeet Kaur, Goutham Patil, Daniel M Geynisman, Pooja Ghatalia> ;Therapeutic Advances in Medical Oncology. 2023 Jan 1
• 2 citations
  Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data.
  Daniel D Joyce, Kevin M Wymer, Vidit Sharma, James P Moriarty, Bijan J Borah, Daniel M Geynisman, Elizabeth R Plimack, Brian A Costello, Lance C Pagliaro, Stephen A Bo...> ;Cancer. 2022 Dec 15
• 11 citations
  Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
  Kevin K Zarrabi, Elizabeth Handorf, Benjamin Miron, Matthew R Zibelman, Fern Anari, Pooja Ghatalia, Elizabeth R Plimack, Daniel M Geynisman> ;The Oncologist. 2023 Feb 8
• 2 citations
  Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma.
  Kevin K Zarrabi, Oladimeji Lanade, Daniel M Geynisman> ;Cancers. 2022 Sep 22
• 1 citations
  Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
  Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T Bourlon, Viviana Del Tejo, Ella X Du, Xiaoran Yang, Selvam R Sendhil, K...> ;The Oncologist. 2023 Jan 18
• 32 citations
  Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
  Nizar M Tannir, Neeraj Agarwal, Camillo Porta, Nicola J Lawrence, Robert Motzer, Bradley McGregor, Richard J Lee, Rohit K Jain, Nancy Davis, Leonard J Appleman, Oscar ...> ;JAMA Oncology. 2022 Oct 1
• The past, present, and future of pT0 in bladder cancer clinical trials.
  Jared P Schober, Elizabeth Plimack, Daniel M Geynisman, Matthew Zibelman> ;Current Opinion in Urology. 2022 Sep 1
• 1 citations
  Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-st...
  Gregory Hemenway, Bianca Lewis, Pooja Ghatalia, Fern Anari, Elizabeth R Plimack, Rutika Kokate, Elizabeth Handorf, Mengying Deng, Daniel M Geynisman, Matthew Zibelman> ;European Urology Oncology. 2023 Aug 1
• Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
  Benjamin Miron, Elizabeth Handorf, Kevin Zarrabi, Matthew R Zibelman, Fern Anari, Pooja Ghatalia, Elizabeth R Plimack, Daniel M Geynisman> ;Urologic Oncology. 2022 Oct 1
• Join now to see all